GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Inc (FRA:1D5A) » Definitions » Institutional Ownership

PLx Pharma (FRA:1D5A) Institutional Ownership : 2.55% (As of Jun. 11, 2024)


View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PLx Pharma's institutional ownership is 2.55%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PLx Pharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PLx Pharma's Float Percentage Of Total Shares Outstanding is 98.14%.


PLx Pharma Institutional Ownership Historical Data

The historical data trend for PLx Pharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PLx Pharma Institutional Ownership Chart

PLx Pharma Historical Data

The historical data trend for PLx Pharma can be seen below:

2022-07-31 2022-08-31 2022-09-30 2022-10-31 2022-11-30 2022-12-31 2023-01-31 2023-02-28 2023-03-31 2023-04-30
Institutional Ownership 13.92 14.92 11.75 11.11 11.05 3.26 3.04 3.01 2.84 2.55

PLx Pharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


PLx Pharma (FRA:1D5A) Business Description

Traded in Other Exchanges
N/A
Address
8 The Green, Suite 11895, Dover, DE, USA, 19901
PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.

PLx Pharma (FRA:1D5A) Headlines

No Headlines